Alternative Management of Giant Omphalocele |
| Giant
omphalocele (GO) remains one of the most formidable challenges in
neonatal surgery. Its definition lacks consensus across the literature
— most authors require either a defect of 5 cm or more in
diameter and/or significant liver herniation within the sac, though
some set the threshold at 7 cm or specify that more than 50–75%
of the liver must be contained — but regardless of the precise
criterion used, GO is not simply a structural anomaly — it is a
condition embedded in a web of associated malformations, pulmonary
hypoplasia, cardiac defects, and chromosomal aberrations that together
dictate its prognosis far more than the defect size alone. Omphalocele occurs in approximately 1 in 4,000 to 10,000 live births, and its incidence continues to decline in regions where prenatal screening leads to elective termination of pregnancies complicated by severe associated anomalies. Yet for those infants who are born with giant omphalocele, the surgical and neonatal teams face a condition for which no universally accepted treatment protocol exists. The fundamental problem is biomechanical. The abdominal cavity has never fully developed to accommodate the herniated viscera, and any attempt at immediate primary closure risks catastrophic intra-abdominal hypertension, abdominal compartment syndrome, respiratory failure, and death. This visceroabdominal disproportion has driven clinicians to devise a wide spectrum of approaches, ranging from purely nonoperative strategies that allow epithelialization of the sac over months or years, to minimally invasive staged reduction techniques that aim for definitive fascial closure within the first weeks of life. Understanding how these approaches evolved — and how they compare — is essential for the modern pediatric surgeon. For decades, the nonoperative "paint-and-wait" strategy served as the default approach for infants whose comorbidities made early surgery prohibitive. This method involves the application of topical escharotic or antimicrobial agents — most commonly silver sulfadiazine, silver-impregnated dressings, or povidone-iodine — to the intact omphalocele membrane, allowing progressive desiccation, eschar formation, granulation tissue development, and ultimately epithelialization of the sac surface. The resulting ventral hernia is then repaired electively, often years later, when the child is larger and physiologically more robust. Advocates of this approach note its low early mortality, avoidance of neonatal anesthesia, and allowance of early enteral feeding. A systematic review by Bauman and colleagues, frequently cited across the literature, concluded that nonoperative delayed closure was associated with lower mortality and faster achievement of full enteral feeding compared to early staged surgical approaches. However, the morbidity and social costs of leaving a child with an unrepaired giant abdominal wall defect for years, the risk of infection, and the need for eventual complex surgical reconstruction are real and significant limitations. The question of which topical agent to use within the paint-and-wait paradigm has itself generated debate. Dörterler, reporting on 22 infants treated in Turkey, described a protocol combining daily povidone-iodine application with a powdered antibiotic spray (polymyxin B, bacitracin, and neomycin) and circumferential elastic bandaging using a cohesive elastic wrap. In this series, conservative management lasted a mean of 11 days before early graft closure was performed, with a mean total hospital stay of only 35 days among survivors. Seven patients died in the first week, all with larger defects and higher rates of complications — a sobering reminder that even with optimized topical care, the most severe cases carry a mortality approaching 30%. The elastic bandaging component of this protocol deserves attention. By providing gentle circumferential compression from xiphoid to pubis, it facilitates gradual reduction of sac contents while supporting repositioning of the liver toward the midline, effectively functioning as a noninvasive silo. This principle — gradual, controlled external compression to recruit abdominal domain — is the conceptual thread that runs through virtually all the alternative strategies reviewed here. Kogut and Fiore formalized this concept with their serial taping technique, reported from a Las Vegas tertiary children's hospital. In their series of 10 infants treated between 2010 and 2017, the omphalocele sac was serially taped at the bedside in the NICU using Mastisol adhesive and strips of clear Tegaderm applied in a criss-cross fashion across the defect. No infant underwent an attempt at primary closure first. Tape was applied daily in successive layers, maintaining forward tension on the lateral abdominal wall muscles while gently reducing the volume of the amniotic sac. Crucially, this was done on the awake infant — a built-in safety mechanism, since an awake baby cannot be taped too tightly without protest. The mean time to operative closure was 13.7 days. Six of the ten infants achieved primary fascial closure without any mesh; four required a small Gore-Tex patch, most of which were subsequently removed and replaced with primary repair. This approach is compelling in its simplicity. It requires no special materials beyond adhesive tape and skin preparation, avoids operative anesthesia during the reduction phase, preserves the fascial edges and amnion intact, and keeps the option of topical escharotic therapy available if the method fails. Complications were minimal, and sac integrity was maintained in all cases until operative closure. The most technically sophisticated evolution of the staged reduction concept is the nonsurgical silo technique described by Abello and colleagues, developed over 25 years at institutions in Colombia and Chile. Their technique employs DuoDERM hydrocolloid dressing cut in a "T" shape, fixed bilaterally to the skin lateral to the defect and wrapped around the omphalocele sac to construct a 360-degree silo without a single suture. Tongue depressors placed at the apex of the silo serve as gentle clamps that are progressively tightened every one to two days under continuous monitoring of intra-abdominal pressure, with a strict ceiling of 20 cm H2O. The protocol unfolds in three phases: silo reduction until the liver and bowel are fully reintegrated (Phase 1), amnion inversion with skin edge approximation to simulate definitive closure and assess tolerance (Phase 2), and definitive surgical closure in the operating room (Phase 3). In a multicenter retrospective cohort of 40 patients spanning 1994 to 2019, anatomical closure was achieved in 95% of cases, median time to closure was 12 days, and there were no deaths attributable to the technique itself. The four deaths observed were all related to severe associated cardiac or pulmonary conditions — precisely the comorbidities that drive mortality in GO regardless of surgical approach. A parallel retrospective cohort study by Barrios-Sanjuanelo and colleagues specifically analyzed mortality predictors among 30 neonates treated with the Abello technique in Barranquilla, confirming an overall mortality rate of 16.7% — well within the 13–25% range typically cited for giant omphalocele — with mortality significantly associated with the presence of other malformations, congenital heart defects, pentalogy of Cantrell, and pulmonary hypertension. Critically, no mortality was associated with technique-related complications, silo reduction time, or abdominal closure timing. This finding reinforces a principle that is now widely accepted but not always acted upon. In giant omphalocele, survival is determined far more by associated anomalies than by the choice of surgical technique. This has important implications for counseling families and for designing future comparative studies. For the subset of patients in whom neonatal closure is not achievable and "paint-and-wait" becomes the de facto management, the challenge eventually becomes one of delayed fascial reconstruction, often years later. Boglione and colleagues from Buenos Aires reported their experience using the San Martín technique — an anatomo-physiological procedure originally described for large midline incisional hernias in adults — for the delayed closure of giant omphaloceles in eight children at a median age of six years. The technique involves bilateral curvilinear release incisions on the outer aspect of the anterior rectus sheath, mobilizing aponeurotic flaps medially and suturing them together at the midline over the posterior sheath, followed by approximation of the rectus muscles and any remaining anterior sheath. No prosthetic mesh was required in any of the eight patients. Median postoperative mechanical ventilation was three days, enteral feeding resumed at a median of four days, and hospital stay was ten days — strikingly efficient outcomes for what represents some of the most complex abdominal wall reconstruction in pediatric surgery. There were no complications attributable to the technique itself during follow-up ranging from 18 months to eight years. Finally, at the frontier of adjunctive therapies, Armijo and colleagues described the combined use of preoperative botulinum toxin A injections and subfascial tissue expanders in a four-year-old boy with giant omphalocele and multiple comorbidities including chronic lung disease, tracheostomy, and pulmonary hypertension. Botulinum toxin A, injected under ultrasound guidance into the transversus abdominis, internal oblique, and external oblique muscles bilaterally, induces a reversible flaccid paralysis of the lateral abdominal wall musculature that peaks at four to six weeks and subsides over three months. This chemically induced muscle relaxation reduces fascial tension at closure, decreases intraabdominal pressure, and may even attenuate postoperative pain by inhibiting the release of substance P and glutamate. When combined with the domain-expanding effect of the tissue expanders, definitive midline fascial closure was achieved with the patient remaining complication-free at nine months postoperatively. Taken together, these six bodies of work map a continuum of therapeutic strategies for giant omphalocele that is far richer — and far more nuanced — than the binary "operate early versus paint-and-wait" framing that has historically dominated the literature. The choice among serial taping, elastic bandaging with topical agents, nonsurgical silo reduction, delayed fascial reconstruction with anatomical techniques, or botulinum toxin augmentation is not simply a matter of surgeon preference; it must be individualized to the infant's physiology, the severity of associated anomalies, the institutional resources available, and a candid assessment of what the family can sustain over what may be a months- or years-long treatment course. What the evidence increasingly supports is that gradual, monitored, external pressure — however it is applied — is the key mechanism driving successful domain recruitment, and that the infant's associated comorbidities, not the defect itself, are the true arbiters of survival. References: 1- Kogut KA, Fiore NF. Nonoperative management of giant omphalocele leading to early fascial closure. J Pediatr Surg. 53(12):2404-2408, 2018 2- Barrios-Sanjuanelo A, Abelló-Munarriz C, Cardona-Arias JA. Mortality in neonates with giant omphalocele subjected to a surgical technique in Barranquilla, Colombia from 1994 to 2019. Sci Rep. 11(1):310, 2021 3- Abello C, A Harding C, P Rios A, Guelfand M. Management of giant omphalocele with a simple and efficient nonsurgical silo. J Pediatr Surg. 56(5):1068-1075, 2021 4- Boglione M, Aleman S, Reusmann A, Rubio M, Marcelo B. Giant omphalocele: Delayed closure using the San Martin technique following epithelialization of the membrane. J Pediatr Surg. 56(6):1247-1251, 2021 5- Armijo AJ, Calvano J, Thomason NT, Arndt C, Shetty AK, Byrd D, Falcon R, Petersen TR, Soneru C. Successful Administration of Preoperative Botox for Giant Omphalocele Repair With Ultrasound Guidance. Cureus. 15(4):e37850, 2023 6- Rombaldi MC, Barreto CG, Feldens L, Holanda F, Takamatu EE, Schopf L, Peterson CAH, Costa EC, Cavazzola LT, Isolan P, Fraga JC. Giant omphalocele: A novel approach for primary repair in the neonatal period using botulinum toxin. Rev Col Bras Cir. 50:e20233582, 2023 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|